Currently, three non-invasive methylation biomarkers—N-Myc downstream-regulated gene 4 (NDRG4), Bone Morphogenetic Protein 3 (BMP3), and Septin 9 (SEPT9)—have received approval from the Food and Drug Administration (FDA) for CRC screening [5, 22]. This evidence concerns the gene SEPTIN9 and colorectal carcinoma.